AUTHOR=Zhang Wenqi , Huang Chen , Liu Ruixia , Zhang Huichao , Li Weijing , Yin Shaoning , Wang Lianjing , Liu Wei , Liu Lihong 

TITLE=Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

JOURNAL=Frontiers in Immunology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.983934

DOI=10.3389/fimmu.2022.983934

ISSN=1664-3224

ABSTRACT=<p>Current therapeutic strategies for central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) are extremely limited. Secondary central nervous system lymphoma (SCNSL) also shows a grave prognosis and high mortality. This report describes a young female patient with DLBCL and CNS relapse who received low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy followed with Bruton’s tyrosine kinase inhibitor and programmed cell death protein 1 antibody after several lines of chemotherapy. However, limited reports on CAR-T cell therapy are applied for SCNSL, particularly those in combination with targeted agents. The current treatment combination for this case provides a new regimen for CNS relapse from DLBCL.</p><sec><title>Clinical Trial Registration</title><p>ClinicalTrials.gov number, NCT04666168.</p></sec>